Highlights from the Two-Year Follow-Up Results of the ZUMA-3 Trial
June 28th 2022
An oncologist specializing in the treatment of patients with B-ALL discusses the study design, efficacy, safety, and two-year updated results of the phase I/II ZUMA-3 study evaluating brexucabtagene autoleucel in adult patients with R/R B-ALL.